Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Jul 30, 2021 - Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates

Jul 30, 2021

Sun Pharma share price rose over 10% today to a 52-week high of Rs 780 on the BSE, after the company reported strong results for the June quarter.

Its bottomline surged 73% year on year (YoY) to Rs 19.8 bn. The reported net profit in the same quarter stood at Rs 14.4 bn.

Strong operational performance

Sun Pharma was able to post good set of numbers mainly due to its robust operational performance.

The company reported consolidated sales of Rs 96.7 bn, a growth of 29% over last year. If compared sequentially, sales were up 14%.

Topline figures beat estimates as the street was expecting Sun Pharma to post a 19.5% revenue growth for the quarter.

The growth in revenues was due to 39% YoY jump in domestic formulations to Rs 33.1 bn. It can also be attributed to the 35% YoY rise in US formations business to Rs 28 bn.

--- Advertisement ---
[Alert] Sell These 3 Stocks Immediately

These 3 stocks are ticking time bombs in your portfolio.

It is very likely that you could be owning these 3 overvalued...

fundamentally weak... ready to crash stocks... in your portfolio today.

Because many stock brokers have painted rosy pictures of these stocks. But the reality is starkly different.

If the market crashes, then these stocks could wipe out your wealth.

You should get rid of these stocks as soon as possible.

We are going to reveal details of these 3 landmines at our upcoming special event at 5 pm on September 24.

You can click here to sign-up. It's free

The topline base for the year-ago quarter was also low, which was affected by the national lockdown in India and reduced sales in major export markets.

EBITDA jumped 59% YoY to Rs 27.7 bn.

Sun Pharma spent more towards its R&D amounting to Rs 5.9 bn, a jump of 41% from the year-ago quarter.

In a press release, Sun Pharma's MD Dilip Shanghvi said,

  • We witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sales of Covid products. We are enthused by the all-round growth across all our businesses compared to Q4 last year.

During the quarter, Sun Pharma repaid debt of about US$185 m. Over the last five quarters, the company has repaid debt of about US$765 m.

Business segments

Sun Pharma is ranked as the top company and holds above 8% market share in the Indian pharma market as per AIOCD AWACS MAT June-2021 report.

For the June quarter under review, the company launched 13 new products in the Indian market.

Sale of branded formulations in India were reported at Rs 33,084 m, up 39% YoY. US sales accounted for 29% of the total consolidated sales and rose 35% YoY.

Its emerging market sales were at US$218 m, a growth of 25% YoY. Meanwhile, Sun Pharma's external sales of API were down 7% YoY.

REVEALED: 3 "Super Smallcaps" You Didn't Know About

Relieved by the lawsuit

During the quarter, the company reported a one-time exceptional loss of Rs 6.3 bn in relation to payments made for settlement of antitrust litigations.

For this, the drugmaker has already made provisions of Rs 4.4 bn.

Further, the company took charge of Rs 1.5 bn during the quarter for impairment of acquired intangible assets under development and Rs 0.4 bn write down of assets.

Note that this settlement is a major relief for the company and its subsidiary as it remained an overhang on earnings given that it could have led to criminal and civil action against the company if found guilty in the US courts.

Equitymaster on the pharma sector

We reached out to Tanushree Banerjee, Co-Head of Research at Equitymaster, and editor of the premium stock recommendation service StockSelect, for her view on the pharma sector.

Here's what she has to say...

  • The second Covid wave has given a new lease of life to pharma stocks. As the sector continues to invest in capacities for new drugs, the profitability will depend on the companies' ability to seek USFDA approval for the plants.

    Or their ability to tie up with MNC pharma for producing variants of their vaccine.

--- Advertisement ---
INSIDER SECRET: An Astonishingly Easy Way to Pile Up Potentially 40-60% Gains in Just 1 Year

India's most well-connected trader with over 35 years of experience just confessed...

"This Lucrative Market Segment Could Leapfrog Over Nifty in The Next 12-16 Months"

... thanks to a massive and irreversible mega-trend fueling its growth!

In fact, he and his partner have already identified 2 spectacular stocks from this segment... which are ready to rake in potentially 40-60% gains in just 1 year... and make you big, fat profits!

The best part of them all...

Their Details Are Packed in This Special Report (Discover How to Claim it for Free)

How the markets reacted to Sun Pharma's earnings

Sun Pharma share price opened the day on a flat note at Rs 704 compared to its previous close of Rs 703.25.

Just after the company announced its results during market hours, its shares saw a spike and rose over 10% to a new 52-week high.

Over the past year, Sun Pharma shares have gained 38%.

At the current price of Rs 774, the company commands a marketcap of Rs 1,857 bn.

About Sun Pharma

Sun Pharma including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked 1st in India and 8th in the US.

It's the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.

The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.

It includes generics branded generics complex or difficult to make technology intensive products over-the-counter (OTC) products anti-retrovirals (ARVs) Active Pharmaceutical Ingredients (APIs) and intermediates.

To know more about the company, check out Sun Pharma company fact sheet and quarterly results.

For a sector overview, read our pharmaceuticals sector report.

You can also compare Sun Pharma with its peers.

Sun Pharma vs Lupin

Sun Pharma vs Alembic Pharma

Sun Pharma vs Natco Pharma

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates". Click here!


More Views on News

Sun Pharma's Stock Falls 4% After Its March Quarter Results (Views On News)

May 28, 2021

In the past three months, the stock has outperformed the market by gaining nearly 20%. Can it go higher?

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)

Aug 16, 2021

The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.

More Views on News

Most Popular

5 Small-cap Stocks with Zero Debt (Views On News)

Sep 3, 2021

In this article, you will get a list of 5 debt free small-cap companies that are worth tracking.

Sansera Engineering IPO: Key Points to Consider (Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore (Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

Put the Odds in Your Favour to Find Smallcap Multibaggers (Profit Hunter)

Sep 3, 2021

A handy checklist to find multibagger smallcaps.

The Top Stocks to Sell in this Bull Market (Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Sep 16, 2021 (Close)


  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks